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Abstract
Background: One of the most important tuberculosis control action represents the effective anti-tuberculosis treatment. The standard regimens are 
associated with high level of side effects, especially at patients with hepatobiliary and pancreatic co-morbidities.
Material and methods: There were studied clinical and laboratory indices of a total number of 60 new pulmonary tuberculosis cases, with proved 
hepatobiliary and pancreatic comorbidities, distributed in the 1st study group, consisted of 30 patients treated with the standard anti-tuberculosis 
treatment, all drugs being administrated orally and the 2nd control group, consisted of 30 patients, treated with the standard anti-tuberculosis treatment 
with injected forms of first line anti-tuberculosis drugs isoniazid and rifampicin. 
Results: The clinical improvement of the patient’s general state under the influence of intravenous use of isoniazid and rifampicin was confirmed by a lower 
expressiveness of intoxication and bronchopulmonary syndroms, as well as by a better radiological dynamics and higher rate of microscopic convertion at 
the end of intensive phase of the tuberculosis treatment. Biochemical disturbances due to tuberculosis treatment were less evident at the patients treated 
with intravenous isoniazid and rifampicin, confirmed by a better rehabilitation of mathematic indices of endogenous intoxication.
Conclusions: Assessing the differences between the clinical and laboratory tolerance of tuberculosis drugs according to the way of administration, it 
was proved the importance of individualization of the standard treatment at patients with hepatobiliary and pancreatic disorders by intravenous use of 
isoniazid and rifampicin in intensive phase of the treatment, for improving the therapeutical effectiveness.
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Background
One of the most important tuberculosis control action 
represents the effective anti-tuberculosis treatment that is 
the most important tool for interrupting the epidemiological 
chain of infectious transmission. As well as, other aims of 
specific treatment represent: the restoring of health, quality 
of life and patient’s productivity, prevention of death due to 
tuberculosis (TB) and relapse, and prevention of acquiring of 
drug resistance [9, 15]. According to World Health Organiza-
tion (WHO) Treatment Guidelines anti-TB drugs are classi-
fied into five groups, based on evidence of efficacy, potency 
and drug class. First-line anti-TB drug, also called essential 
first-line drugs, are recommended in a four-drug regimen, 
containing: isoniazid, rifampicin, pyrazinamide, etambutol for 
the treatment of drug-susceptible TB in the frame of so-called 
Directly Observed Therapy (DOT) [15]. DOT by definition 
means watching the patients swallowing each dose of anti-TB 
drugs [9]. In the frame of actually used Directly Observed 
Treatment Short Course Chemotherapy strategy (DOTS), the 
anti-TB treatment is standardized, meaning that all patients 
receive the same regimens, being included in well-defined 
groups. The standard treatment has advantages over individu-
alized treatment by preventing prescription errors, appropriate 
appreciation of drug needs, distribution and monitoring. By 
economical mean, standard treatment shows reduced costs 
and permits a comparable evaluation of treatment outcomes 
[9]. For standard treatment, the patients are grouped accor-
ding the prior anti-TB treatment course: new patients are the 
cases who have no history of a prior TB treatment or who 
received less than 1 month the anti-TB drugs and previously 
treated patients, includes patients who relapsed, who failed 
the prior treatment and patients returned after default.  The 
total duration of the drug susceptible treatment at new patients 
is 6 months and consists of intensive phase, lasting 2 months 
and continuous phase (ambulatory phase), lasting 4 months. 
During the intensive phase 4 first-line TB drugs (IHN, RIF, 
PZA, EMB) are recommended and during the continuous 
phase 2 drugs are used (IHN, RIF). The main form of first 
line TB-drug administration is oral solid form that is used in 
most of cases. Oral administration is the most simple, has a 
lower price, but is associated with a higher rate of side effects 
in cases with associated gastro-intestinal disorders [13]. Des-
pite simple administration, the oral form of some drugs can 
determine from minor to major side effects in certain medical 
conditions (patients with liver, kidney diseases, gastro-in-
testinal disturbances) or associated harmful habits (alcohol 
abuse). Actually used anti-TB standard regimens, established 
according to WHO recommendations are associated with a 
variable rate of adverse drug reactions (10–15%) diminishing 
their effectiveness, due to treatment individualization accor-
ding to clinical and laboratory tolerance [14]. In most cases 
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the treatment does not show significant (major) adverse drug 
effects. Clinical monitoring of the treatment is essential for 
recognizing adverse drug effects [9]. As well as, it permits the 
prompt and correct management of disturbances appeared 
due to the TB treatment. Minor side effects (jaundice, nausea, 
vomiting) permit the continuation of TB treatment with an 
associated symptomatic treatment. If the patient develops a 
major side-effect, the responsible drug is stopped and the pa-
tient is referred to a specialized health care facility for further 
management [14]. The most frequent major side effect of the 
anti-TB drugs is skin rash (itchy rash) that can be developed 
by any drug: isoniazid, rifampicin, pyrazinamide, or strep-
tomycine. Jaundice (without laboratory evidence of hepatitis) 
and toxic hepatitis can be induced by isoniazid, rifampicin, 
or pyrazinamide [14]. Drug-induced hepatotoxicity appears 
more often in multi-drug TB regimens [13]. The single for-
mulated isoniazid - rifampicin form reports more numerous 
side effects than the form with one agent used alone [13]. The 
risk of drug-induced hepatitis is increased by the associated 
gastrointestinal disorders, liver and kidney diseases, alcohol 
abuse, and wrong diet [13]. As well as, confusion and nervous 
impairment can indicate drug-induced acute liver failure, if it 
is associated with jaundice. The development of acute renal fa-
ilure, purpura, as major side effects and nausea and abdominal 
pain, distinguished as minor side effects permits to suspect the 
involvement of rifampicin in adverse drug reaction [14]. For 
the detection of the drug which induced hepatotoxic effects, 
all anti-TB drugs must be stopped, and then reintroduced one 
by one, at lower dosage till the establishment of the clinical 
and laboratory tolerance [9]. The mechanism of liver injury is 
the induction of cytochrome P450 enzyme by isoniazid and/
or rifampicin, which increases the quantity of toxic metabo-
lite formed by another drug. In addition to this, rifampicin 
impairs bilirubin uptake, resulting in elevated bilirubin levels 
without elevation of transaminases [13]. For clear reasons, 
patients with hepatobiliary and pancreatic disorders have 
an increased susceptibility to develop drug-induced injury 
that permits the individualization of the standard regimen. 
Individualization of standard regimens determines reducing 
of dosage, increasing of treatment duration that impairs the 
efficacy and predisposes to non-adherent patient’s behavior 
[10]. Spectacular, in some cases the anti-TB treatment can 
cause the enlargement of lung inflammation and progression 
of parenchymal destructions [6]. Such side effects are probably 
due to the development of hypersensitivity to mycobacterial 
antigens and development of immune disturbances, during 
the first weeks of the treatment [6].
For the treatment of drug-resistant tuberculosis are used 
second line anti-TB drugs. It requires extensive chemotherapy 
for two years, shows a higher rate of side effects, and a lower 
effectiveness. Intensive phase lasts 6 months and requires 
injected drugs, such as aminoglycosydes and injected fluo-
roquinolones [14]. Only streptomycin, the component of ami-
noglycoside class is used in injected form for the treatment of 
drug-susceptible tuberculosis in certain conditions (children 
less than 7 years old, disseminated TB), other aminoglyco-
sides (kanamycin and amikacin) are used in the treatment 
of multidrug-resistant TB. Fluoroquinolones expose high 
bactericidal activity, used in oral, as well as in injected form 
in the frame of standard regimens of multidrug-resistant TB 
and poli-resistant TB [14]. 
Despite important financial resources involved, the treat-
ment effectiveness in Eastern European States is lower than 
the European average [2, 8, 10]. Due to this, two injected 
forms of first – line anti-TB drugs: isoniazid and rifampicin 
are currently in the course of implementation for the treat-
ment of susceptible TB in the intensive phase performed in 
hospital conditions. According to the published data, average 
of maximum concentration of 450 – 600 mg of intravenous 
injected rifampicin is 22,9 ±2,3 µg/ml, that is 2,5 times higher 
than the same dose administrated orally 8,9 ±1,3 µg/ ml [7]. 
As well as, the minimal inhibitory concentration of injected 
rifampicin is 10 times lower than the oral form (0,03 and re-
spectively 0,3 µg/ml). Considering all scientific review data, 
it was identified a limited number of studies, exposing the 
comparative rate of effectiveness and tolerability of first-line 
injected and oral drugs in the treatment of TB in cases with 
associated gastro-intestinal disorders. 
Aim of the study represented the assessment of treatment 
efficacy of injected forms of isoniazid and rifampicin at pati-
ents with hepatobiliary and pancreatic comorbidities. 
Material and methods
A prospective, descriptive, case-control study was realized 
including 60 new pulmonary infiltrative drug-susceptible 
cases, with hepatobiliary and pancreatic comorbidities. The 
study was performed during the period 1.1.2013 – 1.1.2014. 
Patients were hospitalized in the Chernavtsy Regional Clini-
cal Phtysiopneumological Dispensary. All selected patients 
were microscopically positive for acid fast bacilli and were 
treated according to the established new case category. Pati-
ents were distributed in a study group, composed of 30 cases 
treated with oral forms of isoniazid and rifampicin and the 
control group, composed of 30 cases treated with injected 
forms of first-line anti-TB drugs (isoniazid and rifampicin). 
The rest of associated first-line anti-TB drugs (pyrazinamide 
2000 mg and ethambutol 1200 mg) were used in oral form. 
First-line injected drugs were rifampicin (Ріфонат, «Юрія-
Фарм» [Rifonat, «Uriya-Pharm»], Ukraine) 30 mg/ml (600 
mg) solved in 100 ml of physiological solution of NaCl and 
injected intravenous; isoniazid (Бітуб, «Юрія-Фарм», [Bitub, 
«Uriya-Pharm»], Ukraine) 100 mg/ml (300 mg) solved in 100 
ml of physiological solution of NaCl and injected intravenous. 
General established results: men vs women rate was 3/1, with 
predominance of men in both groups and a medium age of 
patients was established 39,6 ± 1,3 years old in SG and 38,7± 
1,6 years old in CG. So, according to age and sex distribution, 
the patients were similarly distributed, that permitted a com-
parable assessment of selected groups. Hepatobiliary and pan-
creatic disorders were diagnosed using abdominal echography 
and liver functional tests: serum albumin, bilirubin (direct 
and indirect), transaminases (ALT, AST), serum creatinine 
and urea, timol test. The level of endogenous intoxication was 
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appreciated according to Intoxication Leucocytaire Index (ILI) 
Kalf-Kalif (1) and Leucocytaire Shift Yabluchianskii Index 
(LSYI) (2), using the formulas [1, 5]:
ILI Kalf-Kalif = (4М+3Y+2P+S)*(P+1)/Ly+М+Е+B (1)
Normal value = 0,3-1,5 Conventional Units (c.u.).
LSYI = Е+B+P+S/limphocytes +monocytes (2)
Where: M – monocytes, Y – young neutrophyles, P – 
plasmocytes, S – segmented neutrophyles, Ly – lymphocytes, 
E – eosinophyles, B – basophyles. Normal value = 1,5 – 2,2 
Conventional Units (c.u.).
Hematological Index of Intoxication (HII) was calculated 
according to the formula (3) [4]:
HII = ILI * KESR *KL (3)
Where KESR  is the correctional coefficient calculated 
according to erythrocyte sedimentation rate: KESR = 1, if the 
ESR is < 5 mm/hour, KESR increases by 0,1 unit  for each 5 
mm/hour if the ESR is between 5 mm/hour and 30 mm/hour, 
increases by 0,2 unit for the each 5 mm/hour if the ESR is abo-
ve 30 mm/hour. KL is the correctional coefficient calculated 
according to leucocytes quantity. If the leucocytes quantity is 
till 5 * 106/ml the KL is 1 unit and increases by 0,1 unit if the 
leucocytes quantity is more than 8 * 106/ml.
Lymphocytes Index was approved as being the report of 
lymphocytes to neutrophyles: LyI=Ly/N; Normal value = 0,5-
0,65 Conventional Units (c.u.).
For statistical assessment were used the methods of: 
comparision, synthesis and discriminant analysis. Microsoft 
Excel XP and SPSS were used for performing quantitative 
and qualitative assessment. The degree of conclusion was 
established to be <0,05.
Results and discussion
Clinical efficacy of injected/oral forms of first-line anti-
Tb drugs isoniazid and RIF was assessed after 2 months of 
treatment according to specially developed symptomatology 
scale of intoxication syndrom (included such clinical signs: as-
thenia, anorexia, loss of weight, underweight/cachexia, fever/
subfebril temperature, night sweats) and bronchopulmonary 
scale (included: cough, expectorations, hemoptysis, dyspneea 
grade according to MRC scale, thoracic pain). The clinical 
expressiveness was distributed in levels: high, moderate, low 
and light. It was established that clinical state evaluated thro-
ugh intoxication symptomatology of patients with pulmonary 
TB and hepatobiliary/pancreatic comorbidities at the end of 
intesnive phase was better in CG than in SG (table 1). As well 
as, the bronchopulmonary symptomatology was less expressed 
in the same group after 60 days of intensive therapy.
Despite a non-significant difference of endogenous intoxi-
cation biomarkers between groups of the patients at the onset 
of the study, the specific treatment changed significantly their 
state. So, at the end of intensive phase of the treatment, the 
intoxication index ILI K-K was lower in CG. The rest of indices 
(HII and LSYI) increased in the SG due to more important 
immune disturbances developed at those patients (table 2).
Table 1
Expressiveness of the clinical state at the end of intensive 
phase of TB treatment
Index
Intoxication sdr Bronchpulmonary sdr
SG
(n=30),%
CG
(n=30), %
SG
(n=30), %
CG
(n=30), %
Light 56,7 73,3* 50 80*
Low 33,3 26,7 36,7 13,3*
Moderate 10 - 10 6,7
High - - 3,3 -
Average t°С 37,4±1,1 37,1±0,4
Legend: * - statistical difference between SG and CG, n – number 
of cases.
Radiological dynamics under the influence of different 
forms of anti-TB drugs and duration (60, 90, 120 days of 
intensive phase) showed a more evident difference between 
groups of patients. So, the injected first-line drugs (RIF and 
HIN) established a conclusive positive dynamics (resorbtion 
of parenchimal infiltrates, reduction of lung tissue destructi-
ons) in CG than in SG after 2 and 3 months of the treatment 
(table 3).
Table 2
Comparative expressiveness of the endogenous intoxication biomarkers
Index Sample group(n=20) M±m
Study group
(n=30) M±m
Control group
(n=30) M±m
1 2 1 2
ILI K-K c.u. 1,3±0,5 1,6±0,05 1,8±0,07 1,55±0,07 1,5±0,05*
HII c.u. 1,9±0,46 2,1±0,06 2,99±0,07# 2,13±0,07 2,3 ±0,07*
LSYI c.u. 1,8±0,05 2,1±0,06 2,83±0,05# 1,95±0,05 2,1±0,05*
LyI c.u. 0,6±0,76 0,55±0,06 0,38±0,05 0,46±0,06 0,43±0,05
Legend: ILI K-K – Intoxication Leucocytaire Index Kalf-Kalif, HII – Hematological Index of Intoxication.
LSI – Leucocytaire Shift Index М.І.Yabluchyanskiy, LyI – Lymphocytes Index.
# Statistical difference between the index before (1) and at the end (2) of the intensive phase of the treatment within the group.
* – Statistical difference between SG and CG, sample group – group of healthy individuals.
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Table 5
Biochemical dynamics under different forms and 
duration of TB treatment (M±m)
Biochemical 
Indices Groups 1 2
Albumine (g/)l
SG 72,1±0,59 64,8±0,41
CG 72,4±0,81 71,7±0,67*
Bilirubine (µmol/l)
SG 15,1±0,46 20,3±0,91#
CG 14,9±0,44 16,8±0,48
ASAT (mmol/l)
SG 0,41±0,015 0,58±0,016#
CG 0,40±0,011 0,45±0,013
АLAT (mmol/l)
SG 0,48±0,014 0,63±0,019
CG 0,45±0,012 0,51±0,018
Urea (mmol/l
SG 5,2±0,22 5,4±0,11
CG 5,1±0,18 5,2±0,15
Creatinine (kmol/l)
SG 83,5±0,85 91,8±1,23
CG 81,4±0,53 89,1±1,02
Timol test (c.u.)
SG 3,45±0,22 5,10±0,21#
CG 3,7±0,29 4,31±0,32*#
Legend: # statistical difference between the index before (1) and at 
the end (2) of the intensive phase of the treatment within the group, 
* – statistical difference between SG and CG.
Microbiological assessment, through smear microscopy is 
essential tool for the treatment monitoring according to DOTS 
strategy. So, a conclusive difference between the groups was 
obtained at the end of 2nd and 3rd months of treatment, with 
a higher microbiological convertion in CG than in SG (table 
4). After 3 months of intensive phase, treatment failure was 
established at 6,7% of patients of SG.
Impact on the general state and laboratory tolerance of 
TB-drugs used by different ways (injected or orally) at patients 
with hepato-biliary and pancreatic comorbidities was assessed 
through serological indices of albumine, bilirubine, transa-
minases, urea, creatinine and timol reaction. No differences 
were assessed before starting the treatment. 
At the end of the intensive phase a higher level of albumine 
was established in CG. Timol test established a more elevated 
result in SG than in CG and indicated a higher drug-induced 
hepatotoxicity of oraly adminstrated TB drugs. The establi-
shed fact was proved by the conclusive elevation of bilirubine 
and transaminases in SG at the end of intensive phase. In CG 
elevation of serological biomarkers was established, but the 
statistical threshold was not achieved.
Imagistic exploration of the hepatobiliary system establi-
shed increasing of the right liver lobe at 80,0% of all investi-
gated patients by 0.7 ± 0,71 mm and resulted in a total length 
15,1 ± 1,21 mm, the left liver lobe increased at 73,3% cases 
by 0,82  ± 0,12 mm with a total length 11,2  ± 2,7 mm, the 
signs of diffuse liver damage, expressed as hyperechogenic 
changes and increase of the portal vein size were identified 
at 68,3% cases.
Conclusions
Assessing the differences between the clinical and labo-
ratory tolerance of TB drugs according to the way of admi-
nistration, it was proved the importance of individualization 
of the standard treatment at patients with hepatobiliary and 
pancreatic disorders by intravenous use of isoniazid and 
rifampicin in intensive phase, for improving the quality of 
the TB treatment.
The clinical improvement of the patient’s general state 
under the influence of intravenous use of isoniazid and 
rifampicin was confirmed by a lower expressiveness of in-
toxication and bronchopulmonary syndroms, as well as by a 
better radiological dynamics and higher rate of microscopic 
convertion at the end of intensive phase of the TB-treatment.
Biochemical disturbances due to TB treatment was less 
evident at the patients treated with intravenous isoniazid and 
rifampicin, confirmed by a better rehabilitation of mathematic 
indices of endogenous intoxication.
Table 3
Radiological evolution under different forms and duration of TB treatment
Groups
60 days (n=60) 90 days (n=31) 120 days (n=6)
Positive Negative Positive Negative Positive Negative
% % % % % %
Study group 23,3 3,3 50 21,4 50 25
Control group 47,3* 13,3* 72,7* 45,4* 100 100
Legend:  * - statistical difference between SG and CG, n – number of cases.
Table 4 
Microbiological dynamics under different forms and 
duration of TB treatment
Groups
60 days 
(n=60)
90 days 
(n=31)
120 days 
(n=6)
Treatment 
failure
% % % %
Study group 36,7 73,7 75 6,7
Control group 60* 91* 100 -
Legend:  * – statistical difference between SG and CG, n – number 
of cases.
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